SlideShare a Scribd company logo
9
Most read
13
Most read
15
Most read
α/β:Where does it stand today??
Cell Kill
• Radiation causes damage to the “target”
• Target can be single or multiple
• A lethal event for the cell can occur by the following ways
– Single or multiple hits of single or multiple targets
• A target in a cell could be the nucleus or the cytoplasm
Targets
Mathematical Models
• These depict the survival patterns of studied cells exposed to
a range of radiation doses.
• Two basic models
– Target model
– Repair model
• Most widely used in clinical practice
– Linear-Quadratic model
Target models
• Single hit - single target
• Single hit – multi target
• Two hit – single target [Quadratic ]
• Two component model
Single hit-single target + two hit-single target [Linear-
Quadratic]
Single hit-single target + single hit-multiple target [Multi-
Target]
Single hit on a target
S = e-D/D0 = e-αD
Single hit and multiple hits on targets
S = e-αD-βD2
Multiple hits on a target
S = e-βD2
Single hit/target +
Single hit on multiple targets
S=e-D/1D0[1-(1-e-D/D0)n]
Linear cell survival and Quadratic cell
survival
Concept of α & β
• α : Component of killing which is proportional to the dose
• β : Component of killing which is proportional to square of the
dose.
• S = e -αD- βd
2
and α/β ratio is the dose at which linear and
quadratic components of killing are equal
• E/α = BED = (1 + d / (α/β)) * D = RE * D
Relative Effectiveness (RE)
LQ MODEL IS APPROPRIATE
• Assumptions:
– Cell killing is primarily a result of DNA damage (DSBs)
– For multifractionated treatment, the fractions are well
separated in time
– Irradiation time for EBRT is short and with a constant dose
rate
– α/β for tumour is 10 Gy, and for late complications is 3 Gy
– No tumour repopulation occurs within 2 weeks, and
– LQ modelling is valid up to 23 Gy per fraction
LQ MODEL: Hypo fractionated
Treatments
 In vitro studies: LQ Model fits well between 0-16 Gy
*Garcia LM et al Phys Med Biol 2006;51:2813–2823
 In Vivo studies :Also shows that LQ model reliably predicts
dose response between 2-20 Gy
Barendsen GW et al. Int J Radiat Oncol Biol Phys 1982;8:1981–1997
Van der Kogel AJ. Radiat Res Suppl 1985;8:S208–S216
Peck JW, Gibbs FA. Radiat Res 1994;138:272–281
α/β values: fixed or changing??
• Traditional concept:
– α/β for rapidly proliferating tissues and tumor
– α/β for slowly proliferating tissues and late responding
tissues
• Recent concept:
– α/β values depend on the end points chosen and also proliferating
capacity of tumors
– α/β =3.5 Gy for AV malformations and for <3 cm 4.6-6.4 Gy*
– α/β =1.5-2 Gy $ for for biochemical failure in prostate cancers and
another study reported as α/β >30 Gy #
– α/β =8.5 for well oxygenated and 15.5 for hypoxic colonogens of
prostate cancer@
*Kocher M et al. Radiotherapy and oncology 2004;71:109-114
# Richard Shaffer et al. Int. J. Radiation Oncology Biol.Phy. 2011;79;4:1029-36
$ Bentzen M Soren et al. Radiotherapy and oncology. 2005;76:1-3
@ Nahum A E et al. Int. J. Radiation Oncology Biol.Phy. 2003;57;2:391-401
So What`s the problem??
LQ Model: Application in SRT and
SBRT
 Leith JT et al*. calculated the radiation doses required to
control metastatic brain lesions using data from in vitro
survival curves.
– Found that the calculated dose required to obtain
a high tumour control probability was at least 25
to 35 Gy Vs 15-20 Gy (clinical doses)
 Karlson et al**. Found in the treatment of Arterio-venous
malformations that 42 Gy/12# was more effective than the
equivalent dose of 15 Gy/1# by LQ model
*Acta Neurochir Suppl 62:1827,1994.
**Neurosurg 57:42-49, 2005
What happens when LQ Equation is
used to calculate dose equivalence at
high dose per fraction
 Radiation Effect on Vasculature and supporting cells:
 Ionizing radiation can damage supporting tissue such as microvasculature,
mainly at high doses
 Vascular endothelial damage is triggered above 10 Gy per fraction secondary to
the activation of acid sphingomyelinase*,#
*Garcia-Barros M et al. Science 300:1155-1159, 2003
# Fuks Z et al. Cancer Cell 8:89-91, 2005
 Radiation Effects on tumor stem cells:
 Relatively radio resistant Stem cell play a role in malignant gliomas and other
tumors
 Stem cells have a radiation threshold after which they die (Usually >17-18
Gy)**
**Chang HJ, et al. Nat Med 11:484-490,2005
Modifications of LQ Model
 LQ-L Model: Accounts for high dose per fraction #
# Guerrero M et al. Phys Med Biol 49;4825-4835;2004
 Biophysical Models: To take in to account the dynamic
interaction of radiation and tissues*
– Γ-LQ Model (Kinetic model),
*Scheidegger S, et al. Z Med Phys .2011 Sep;21(3):164-73. 2011
 LQ-R Model: Accounts Redistributions and Re-oxygenation**
** Brenner D J et al,Int. J. Radiation Oncology Biol. Phys.1995;32;2:379-390
Modifications of LQ Model (Cont..)
 Modified LQ Model : Accounts for increased overall treatment
time
E = - ln S = n * d (α + βd) - γT
Including T ("kick off time") which allows for a time lag before
the tumor switches to the fastest repopulation time:
 LQ Model for Low dose rate brachytherapy:
Where g represents how much less effective the repairable
component has become
Survival curve with LQ-L Model
• Adds up the LQ and the
Multi target model.
• Gives Equivalent
functions: SFED (Single
fraction equivalent
dose),BED and SED
(standard effective dose)
for comparison of various
SBRT regimens
LQ Model: High LET vs. Low
LET Radiation
• Assumes high LET radiation
affects α co-efficient of damage
more than β co-efficient.
• Introduced a new parameter
RBEM
αH=αLRBEM
LQ Model: Conclusion I
 It is a mechanistic, biologically-based model.
 It has sufficiently few parameters to be practical
 It is reasonably well validated, experimentally and
theoretically, up to about 10 Gy /fraction, and would be
reasonable for use up to about 18 Gy per fraction
 To date, there is no evidence of problems when LQ has been
applied in the clinic within above constraints.
LQ Model: Conclusion II
 It does not take in to account the non-DNA targets of radiation.
 It overestimates the BED at doses used in SBRT and SRT
treatments.
 It can not be used to equate doses between high LET and low
LET radiations
 It does not take in to account the cell kinetics and interaction
of radiation with other factors.
Thanks
Do we have an
alternative to LQ Model
:No
So we have to stay with
it??

More Related Content

PPTX
Linear quadratic model ppt
PPTX
cell survival curve
ODP
New Techniques in Radiotherapy
PPTX
Altered fractionation kiran
PPTX
Cell survival curve
PPTX
Principals of brachytherapy shk
PPT
Interaction of radiation with Matter - Dr. Vandana
PPT
Radiobiology
Linear quadratic model ppt
cell survival curve
New Techniques in Radiotherapy
Altered fractionation kiran
Cell survival curve
Principals of brachytherapy shk
Interaction of radiation with Matter - Dr. Vandana
Radiobiology

What's hot (20)

PDF
Mind the Gap: Dealing with Interruptions in Radiotherapy Treatment
PPTX
ICRU 38 nayana
PPTX
TIME DOSE & FRACTIONATION
PPTX
Beam modifying devices 1 Radiophysics
PPTX
Total body irradiation
PPTX
Quantec dr. upasna saxena (2)
PPTX
Plan evaluation in Radiotherapy- Dr Kiran
PPTX
Co60 vs Ir192
PDF
Total body irradiation
PPTX
Electron beam therapy
PPTX
Concept of bed in radiobiology
PDF
Hypofractionation in hnc
PPTX
Basics And Physics of Brachytherapy
PDF
Surface Guided Radiotherapy for Accuracy, Volume Reduction, Real time Trackin...
PPTX
Rrecent advances in linear accelerators [MR linac]
PDF
Volumetric Modulated Arc Therapy
PPTX
5 Rs OF RADIOBIOLOGY.pptx
PPTX
EXTERNAL PHOTON BEAMS THERAPY (PART 2)
PPTX
Hyperthermia in radiotherapy
Mind the Gap: Dealing with Interruptions in Radiotherapy Treatment
ICRU 38 nayana
TIME DOSE & FRACTIONATION
Beam modifying devices 1 Radiophysics
Total body irradiation
Quantec dr. upasna saxena (2)
Plan evaluation in Radiotherapy- Dr Kiran
Co60 vs Ir192
Total body irradiation
Electron beam therapy
Concept of bed in radiobiology
Hypofractionation in hnc
Basics And Physics of Brachytherapy
Surface Guided Radiotherapy for Accuracy, Volume Reduction, Real time Trackin...
Rrecent advances in linear accelerators [MR linac]
Volumetric Modulated Arc Therapy
5 Rs OF RADIOBIOLOGY.pptx
EXTERNAL PHOTON BEAMS THERAPY (PART 2)
Hyperthermia in radiotherapy
Ad

Similar to Basics of linear quadratic model (20)

PDF
RB-week10.pdf chapter ten ten chapters c
PPTX
w1joinereqd2illumination16by9animatedplusdproliftoronto23ws.pptx
PDF
To use or not to use the LQ model at “high” radiation doses
PPTX
CELL SURVIVAL CURVE.pptx
PPTX
Srs and sbrt 2 dr.kiran
PPT
IMRT in Head & Neck Cancer
PPT
Radiobiology behind dose fractionation
PPT
7. Radiobiology behind Dose Fractionation.ppt
PDF
The Radiobiology Behind Dose Fractionation.pdf
PPT
Radiobiologia aplicada a física médica e suas aplicações
PPT
Oltre l’alfa/beta: ipotesi di coinvolgimento dell’endotelio e modelli preditt...
PDF
RADIOBIOLOGY GYN MARPLES.pdf
PPTX
HYPOFRACTIONATION IN RADIOTHERAPY
PPTX
HYPOFRACTIONATION.pptx
PDF
2012-michael joiner-hypofractionation
PPT
Radiation oncology
PPTX
Fractionation in Radiotherapy
PPT
Time , Dose & Fractionationrevised
PPTX
Alpha auger emitters
PPTX
Radiation therapy in head and neck cancer
RB-week10.pdf chapter ten ten chapters c
w1joinereqd2illumination16by9animatedplusdproliftoronto23ws.pptx
To use or not to use the LQ model at “high” radiation doses
CELL SURVIVAL CURVE.pptx
Srs and sbrt 2 dr.kiran
IMRT in Head & Neck Cancer
Radiobiology behind dose fractionation
7. Radiobiology behind Dose Fractionation.ppt
The Radiobiology Behind Dose Fractionation.pdf
Radiobiologia aplicada a física médica e suas aplicações
Oltre l’alfa/beta: ipotesi di coinvolgimento dell’endotelio e modelli preditt...
RADIOBIOLOGY GYN MARPLES.pdf
HYPOFRACTIONATION IN RADIOTHERAPY
HYPOFRACTIONATION.pptx
2012-michael joiner-hypofractionation
Radiation oncology
Fractionation in Radiotherapy
Time , Dose & Fractionationrevised
Alpha auger emitters
Radiation therapy in head and neck cancer
Ad

More from Ajeet Gandhi (20)

PPTX
Reirradiation for recurrent Glioma: Approach to diagnosis and management
PPTX
Techniques for Inguinal/Groin Irradiation
PPTX
Radiotherapy practices in GYN malignancies
PPTX
Final simulation protocols in GYN malignancies
PPTX
Evolution of Intracavitary brachytherapy for carcinoma of cervix
PPTX
Axillary radiotherapy versus axillary surgery in breast cancer
PPTX
Hormonal and novel therapies in metastatic breast cancer
PPTX
Post treatment surveillance for Genitourinary Cancers
PPTX
Incorporating data for management of breast cancer
PPTX
Breast cancer screening
PPTX
Hepatobiliary brachytherapy
PPTX
Panel discussion recurrent cervical cancer
PPTX
Role of radiotherapy in recurrent carcinoma cervix
PPTX
Controversies in the management of rectal cancers
PPTX
T4 Larynx cancer can be treated with Chemoradiotherapy
PPTX
Advances in radiation oncology:Cancer care
PPTX
Flash radiation therapy
PPTX
Adenoidcystic carcinoma in head and neck cancers
PPTX
Management of recurrent Glioblastoma and role of Bevacizumab
PPTX
Management of Anemia in cancer patients
Reirradiation for recurrent Glioma: Approach to diagnosis and management
Techniques for Inguinal/Groin Irradiation
Radiotherapy practices in GYN malignancies
Final simulation protocols in GYN malignancies
Evolution of Intracavitary brachytherapy for carcinoma of cervix
Axillary radiotherapy versus axillary surgery in breast cancer
Hormonal and novel therapies in metastatic breast cancer
Post treatment surveillance for Genitourinary Cancers
Incorporating data for management of breast cancer
Breast cancer screening
Hepatobiliary brachytherapy
Panel discussion recurrent cervical cancer
Role of radiotherapy in recurrent carcinoma cervix
Controversies in the management of rectal cancers
T4 Larynx cancer can be treated with Chemoradiotherapy
Advances in radiation oncology:Cancer care
Flash radiation therapy
Adenoidcystic carcinoma in head and neck cancers
Management of recurrent Glioblastoma and role of Bevacizumab
Management of Anemia in cancer patients

Recently uploaded (20)

PPTX
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
PPTX
ACID BASE management, base deficit correction
PPTX
Respiratory drugs, drugs acting on the respi system
PPTX
Note on Abortion.pptx for the student note
PDF
شيت_عطا_0000000000000000000000000000.pdf
PPTX
Imaging of parasitic D. Case Discussions.pptx
PPTX
anal canal anatomy with illustrations...
PPTX
Uterus anatomy embryology, and clinical aspects
PPTX
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
PPTX
CME 2 Acute Chest Pain preentation for education
PPTX
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
PPTX
History and examination of abdomen, & pelvis .pptx
PPT
ASRH Presentation for students and teachers 2770633.ppt
PPTX
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
PDF
NEET PG 2025 | 200 High-Yield Recall Topics Across All Subjects
PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
PDF
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
PPT
Management of Acute Kidney Injury at LAUTECH
PDF
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
ACID BASE management, base deficit correction
Respiratory drugs, drugs acting on the respi system
Note on Abortion.pptx for the student note
شيت_عطا_0000000000000000000000000000.pdf
Imaging of parasitic D. Case Discussions.pptx
anal canal anatomy with illustrations...
Uterus anatomy embryology, and clinical aspects
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
CME 2 Acute Chest Pain preentation for education
DENTAL CARIES FOR DENTISTRY STUDENT.pptx
History and examination of abdomen, & pelvis .pptx
ASRH Presentation for students and teachers 2770633.ppt
Chapter-1-The-Human-Body-Orientation-Edited-55-slides.pptx
NEET PG 2025 | 200 High-Yield Recall Topics Across All Subjects
Medical Evidence in the Criminal Justice Delivery System in.pdf
Oral Aspect of Metabolic Disease_20250717_192438_0000.pdf
Management of Acute Kidney Injury at LAUTECH
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt

Basics of linear quadratic model

  • 1. α/β:Where does it stand today??
  • 2. Cell Kill • Radiation causes damage to the “target” • Target can be single or multiple • A lethal event for the cell can occur by the following ways – Single or multiple hits of single or multiple targets • A target in a cell could be the nucleus or the cytoplasm
  • 4. Mathematical Models • These depict the survival patterns of studied cells exposed to a range of radiation doses. • Two basic models – Target model – Repair model • Most widely used in clinical practice – Linear-Quadratic model
  • 5. Target models • Single hit - single target • Single hit – multi target • Two hit – single target [Quadratic ] • Two component model Single hit-single target + two hit-single target [Linear- Quadratic] Single hit-single target + single hit-multiple target [Multi- Target]
  • 6. Single hit on a target S = e-D/D0 = e-αD Single hit and multiple hits on targets S = e-αD-βD2 Multiple hits on a target S = e-βD2 Single hit/target + Single hit on multiple targets S=e-D/1D0[1-(1-e-D/D0)n]
  • 7. Linear cell survival and Quadratic cell survival
  • 8. Concept of α & β • α : Component of killing which is proportional to the dose • β : Component of killing which is proportional to square of the dose. • S = e -αD- βd 2 and α/β ratio is the dose at which linear and quadratic components of killing are equal • E/α = BED = (1 + d / (α/β)) * D = RE * D Relative Effectiveness (RE)
  • 9. LQ MODEL IS APPROPRIATE • Assumptions: – Cell killing is primarily a result of DNA damage (DSBs) – For multifractionated treatment, the fractions are well separated in time – Irradiation time for EBRT is short and with a constant dose rate – α/β for tumour is 10 Gy, and for late complications is 3 Gy – No tumour repopulation occurs within 2 weeks, and – LQ modelling is valid up to 23 Gy per fraction
  • 10. LQ MODEL: Hypo fractionated Treatments  In vitro studies: LQ Model fits well between 0-16 Gy *Garcia LM et al Phys Med Biol 2006;51:2813–2823  In Vivo studies :Also shows that LQ model reliably predicts dose response between 2-20 Gy Barendsen GW et al. Int J Radiat Oncol Biol Phys 1982;8:1981–1997 Van der Kogel AJ. Radiat Res Suppl 1985;8:S208–S216 Peck JW, Gibbs FA. Radiat Res 1994;138:272–281
  • 11. α/β values: fixed or changing?? • Traditional concept: – α/β for rapidly proliferating tissues and tumor – α/β for slowly proliferating tissues and late responding tissues • Recent concept: – α/β values depend on the end points chosen and also proliferating capacity of tumors – α/β =3.5 Gy for AV malformations and for <3 cm 4.6-6.4 Gy* – α/β =1.5-2 Gy $ for for biochemical failure in prostate cancers and another study reported as α/β >30 Gy # – α/β =8.5 for well oxygenated and 15.5 for hypoxic colonogens of prostate cancer@ *Kocher M et al. Radiotherapy and oncology 2004;71:109-114 # Richard Shaffer et al. Int. J. Radiation Oncology Biol.Phy. 2011;79;4:1029-36 $ Bentzen M Soren et al. Radiotherapy and oncology. 2005;76:1-3 @ Nahum A E et al. Int. J. Radiation Oncology Biol.Phy. 2003;57;2:391-401
  • 12. So What`s the problem??
  • 13. LQ Model: Application in SRT and SBRT  Leith JT et al*. calculated the radiation doses required to control metastatic brain lesions using data from in vitro survival curves. – Found that the calculated dose required to obtain a high tumour control probability was at least 25 to 35 Gy Vs 15-20 Gy (clinical doses)  Karlson et al**. Found in the treatment of Arterio-venous malformations that 42 Gy/12# was more effective than the equivalent dose of 15 Gy/1# by LQ model *Acta Neurochir Suppl 62:1827,1994. **Neurosurg 57:42-49, 2005
  • 14. What happens when LQ Equation is used to calculate dose equivalence at high dose per fraction
  • 15.  Radiation Effect on Vasculature and supporting cells:  Ionizing radiation can damage supporting tissue such as microvasculature, mainly at high doses  Vascular endothelial damage is triggered above 10 Gy per fraction secondary to the activation of acid sphingomyelinase*,# *Garcia-Barros M et al. Science 300:1155-1159, 2003 # Fuks Z et al. Cancer Cell 8:89-91, 2005  Radiation Effects on tumor stem cells:  Relatively radio resistant Stem cell play a role in malignant gliomas and other tumors  Stem cells have a radiation threshold after which they die (Usually >17-18 Gy)** **Chang HJ, et al. Nat Med 11:484-490,2005
  • 16. Modifications of LQ Model  LQ-L Model: Accounts for high dose per fraction # # Guerrero M et al. Phys Med Biol 49;4825-4835;2004  Biophysical Models: To take in to account the dynamic interaction of radiation and tissues* – Γ-LQ Model (Kinetic model), *Scheidegger S, et al. Z Med Phys .2011 Sep;21(3):164-73. 2011  LQ-R Model: Accounts Redistributions and Re-oxygenation** ** Brenner D J et al,Int. J. Radiation Oncology Biol. Phys.1995;32;2:379-390
  • 17. Modifications of LQ Model (Cont..)  Modified LQ Model : Accounts for increased overall treatment time E = - ln S = n * d (α + βd) - γT Including T ("kick off time") which allows for a time lag before the tumor switches to the fastest repopulation time:  LQ Model for Low dose rate brachytherapy: Where g represents how much less effective the repairable component has become
  • 18. Survival curve with LQ-L Model
  • 19. • Adds up the LQ and the Multi target model. • Gives Equivalent functions: SFED (Single fraction equivalent dose),BED and SED (standard effective dose) for comparison of various SBRT regimens
  • 20. LQ Model: High LET vs. Low LET Radiation • Assumes high LET radiation affects α co-efficient of damage more than β co-efficient. • Introduced a new parameter RBEM αH=αLRBEM
  • 21. LQ Model: Conclusion I  It is a mechanistic, biologically-based model.  It has sufficiently few parameters to be practical  It is reasonably well validated, experimentally and theoretically, up to about 10 Gy /fraction, and would be reasonable for use up to about 18 Gy per fraction  To date, there is no evidence of problems when LQ has been applied in the clinic within above constraints.
  • 22. LQ Model: Conclusion II  It does not take in to account the non-DNA targets of radiation.  It overestimates the BED at doses used in SBRT and SRT treatments.  It can not be used to equate doses between high LET and low LET radiations  It does not take in to account the cell kinetics and interaction of radiation with other factors.
  • 23. Thanks Do we have an alternative to LQ Model :No So we have to stay with it??